AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Updates
26/09/22 EPSWe have only changed our short-term est...
23/09/22 EarningsA rather reassuring H1 22
05/09/22 EPSWe have adjusted our numbers to the cur...
05/09/22 NAVWe have adjusted our numbers to the cur...
05/09/22 DCFWe have adjusted our numbers to the cur...
25/07/22 TargetDespite the fact we have quite significant...
25/07/22 EPSOur short-term EPS forecasts have little ...
25/07/22 NAVWe have reviewed our assumptions regar...
25/07/22 DCFDespite the fact we have changed our mi...
22/07/22 LatestThe update of our assumptions confirms ...
20/06/22 LatestA major breakthrough for Crossject
29/03/22 EarningsFY21: not very meaningful, as expected
17/12/21 Financing i...New financing
24/09/21 EarningsH1 21: unsurprising (as usual)
31/08/21 EPSWe have fine-tuned our numbers on the b...
18/08/21 EPSWe have only integrated the detailed num...
18/06/21 LatestAnother good piece of news for the group
17/06/21 LatestA licensing agreement for Zeneo Hydroco...
31/03/21 EarningsFY20 unsuprising; waiting for more
15/12/20 Financing i...A double bond issue
21/09/20 EarningsUpdate on the group's business
22/05/20 EPSNo major changes to our forecasts. The o...
29/03/20 EarningsMeaningless FY19 results and product up...
23/12/19 Financing i...Extra-financing to increase visibility
20/11/19 Financing i...A €2.6m non-dilutive issue
15/10/19 LatestCooperation agreement with the US Dep...
10/09/19 EarningsH1 19: no surprise
10/07/19 Financing i...Warrants to existing shareholders
19/06/19 LatestA commercial success
Target
Upside 196%
Price (€) 3.31
Market Cap (€M) 120
Perf. 1W: -9.81%
Perf. 1M: -15.1%
Perf. 3M: -2.38%
Perf Ytd: 16.8%
10 day relative perf. to stoxx600: -12.8%
20 day relative perf. to stoxx600: -21.7%